ArticleRegenerative biomaterials2025
Engineered collagen XVII-loaded dissolving microneedle patch for promoting hair regrowth in androgenic alopecia.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgenic alopecia (AGA), the most common form of progressive hair loss in both males and females, significantly impacts patients' quality of life and confidence. Current therapies, such as minoxidil, are limited by poor patient compliance and low transdermal bioavailability, highlighting the need for more effective treatments. In this study, we identified collagen XVII (COL17) as a key player in AGA-like model pathogenesis, observing its significant downregulation in a testosterone-induced AGA-like mouse model. This reduction was accompanied by abnormal hair follicle morphology, decreased proliferation and impaired angiogenesis. To address this, we developed recombinant human COL17 fragment (800-1300 aa) (rhCOL17p) expressed and purified from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.